Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall Reports Financials For First Half Year 2009
Almirall has posted net income totalling E103.4m for the first half year 2009, whereas the normalized income reached E89.1m. The company has also reflected a 3.9% rise of
Almirall has posted net income totalling E103.4m for the first half year 2009, whereas the normalized income reached E89.1m. The company has also reflected a 3.9% rise of
Ligand has reported the mutual termination of its collaboration and license agreement with Organon, which Ligand assumed in connection with its acquisition of Pharmacopeia in December 2008. Reportedly,
Transave has entered into a co-operative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),
The Dow Chemical Company and Petroliam Nasional Berhad (PETRONAS) have reached an agreement for Dow’s Union Carbide Corporation subsidiary, to sell its entire shares of ownership in the
SOCMA has warned against the health care reform bill. In a letter to House Speaker Nancy Pelosi and House Minority Leader John Boehner, SOCMA asked the lawmakers to
Pfizer has reached an agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study. Kano State will dismiss
BioMarin has reported that the US Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan, for the treatment of
Quinnova has launched Salvax Duo, which contains one unit of Salvax Foam and one unit of Hydro 40 Foam. Salvax Duo is available by prescription only, and both
Genentech has announced the results of its phase III study – CRUISE for Lucentis (ranibizumab injection). Data showed improved vision, as measured by the primary endpoint of mean
FDA has approved United Therapeutics’ Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH), using the Tyvaso Inhalation System. Tyvaso is indicated to increase walk